Abstract
Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is characterized by dream enactment behaviors and loss of physiological atonia during REM sleep. It is considered a prodromal stage of alpha-synucleinopathies and may result from dysfunction of brainstem structures regulating muscle tone in REM sleep. Whether other REM sleep features are simultaneously affected remains unclear. Here, we investigated alterations in REM sleep microstructure, including phasic REM sleep, sawtooth waves (STW) and non-REM/REM sleep transitions, in iRBD and RBD associated with Parkinson’s disease (PD+RBD). We retrospectively included 20 patients with iRBD (85% male, 66.5[63–68]years), 20 patients with PD+RBD (75% male, 62.5[57.5-65]years) and 20 controls (75% male, 67[61–70]years). REM sleep without atonia (RSWA), bursts of REMs and STW bursts were manually scored. Phasic REM sleep proportion (derived from REMs), STW density/duration/frequency and the duration of NREM/REM transitions were compared between groups with a general linear mixed-effects model. Phasic REM sleep proportion was higher in the iRBD group (26.5[21–33]%) than in control (16.4[12.5-22.3]%, p-corrected=0.005) and PD+RBD (17.6[13.9-21.7]%, p-corrected=0.005) ones. Non-REM/REM transitions showed a duration gradient, increasing from controls (119.0[58.5-186.1]sec) to iRBD (212.1[68.5-391.4]sec, p-corrected=0.0038) and PD+RBD (375.8[217.6-514.6]sec, p-corrected<0.001) patients. STW density and duration were reduced in the PD+RBD group only (1.33[1.1-1.54]/min; 2.13[1.70-2.69]sec) vs controls (1.74[1.52-2.05]/min, p-corrected=0.005; 2.98[2.18-4.11], p-corrected<0.001), whereas altered STW spectral content was observed in both patient’s groups with a power shift toward higher frequencies (both p<0.001 vs controls). These results reinforce the hypothesis that REM sleep dysregulation in RBD extends to REM-specific electrophysiological features beyond loss of muscle atonia and dream enactments.
Statement of Significance This study compared rapid eye movement (REM) sleep microstructure between patients with isolated REM sleep behavior disorder (iRBD) or RBD associated with Parkinson’s disease (PD+RBD), and controls. We found some altered REM sleep features in patient groups versus controls, as increased phasic REM sleep proportion in iRBD and reduced sawtooth waves (STW) density and duration in PD+RBD. Both groups exhibited altered STW spectral characteristics with a shift toward higher frequencies. Additionally, we observed a gradient in the duration of NREM/REM sleep transitions, increasing from controls to patients with iRBD and peaking in patients with PD+RBD, who exhibited the longest transitions. These findings highlight that REM sleep anomalies in RBD extends beyond atonia loss and dream enactments, encompassing broader microstructural changes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JN was supported by the Fondation Pour la Recherche Médicale postdoctoral fellowship (2023-2026), and LC was supported by the Agence Régionale de Santé Auvergne-Rhônes Alpes master fellowship 2023-2024
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was performed in accordance with the principles of good clinical practice and the Declaration of Helsinki. The trial was approved by the Ethic Review Board of the Hospices Civils de Lyon (#23-5452 issued on 21/03/2024). All participants provided informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Shared first authorship
Change in the Acknowledgements website box to match change in the pdf Acknowledgements section.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
